BCAL Strengthens Breast Cancer Screening Access with Sonic Partnership.

BCAL Diagnostics Limited (ASX: BDX) has entered into a significant agreement with Sonic Healthcare Australia Pathology to expand access to its blood-based breast cancer diagnostic test, BREASTEST plus. This test, designed for women with dense breast tissue, has already been successfully trialled across Sydney since its launch in March 2025. Under the new agreement, patients will now have access to the test through 93 Douglass Hanly Moir Pathology centres in Sydney, with specimen processing carried out by Melbourne Pathology.

BCAL’s CEO, Shane Ryan, highlighted that this collaboration marks an important milestone in the company’s commercial rollout, ensuring greater convenience for women and supporting quicker diagnosis and disease management. BREASTEST plus complements mammography, providing additional lipidomic insights to improve breast cancer detection. The staged rollout in Sydney and Melbourne is progressing, with further expansion anticipated in the coming months. This move strengthens BCAL’s commitment to advancing early, accurate, and accessible cancer diagnostics.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com